| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From INSERM U403 and the Departments of Immunology and Rheumatology,* Hôpital Edouard Herriot, Lyon, France; and the Deutsches Rheumaforschungszentrum Berlin, Berlin, Germany
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
-producing cells in both in vitro and in vivo situations. Oligoclonal activation of normal peripheral blood mononuclear cells with the superantigen Staphylococcus aureus enterotoxin B and polyclonal activation with phorbol myristate acetate/phytohemagglutinin were used as in vitro models. This study was extended to various in vivo situations such as rheumatoid arthritis, dermatomyositis, and normal activated lymph nodes. The phenotype of IL-17- and IFN--producing cells was evaluated by immunohistochemistry using the CD3 and CD4 T-cell markers, the CD20, CD38, 
and 
light chain B-cell lineage markers. The expression of two chemokine receptors, CCR6 and CCR7, involved with their associated ligands CCL20 and CCL19/CCL21 in the migration of T lymphocytes, was evaluated in tissue sections. After both polyclonal and oligoclonal activation, IL-17+ and IFN-+ cells acquired a plasma cell-like morphology associated with a high secretory activity, the reduced expression of CD3, and no change of CD4 expression. In rheumatoid arthritis, dermatomyositis, and activated lymph nodes, both IL-17- and IFN--producing cells had the same morphology. These Th1 cytokine-producing cells were CD4+-, CD3-, and B-cell lineage marker-negative. In both in vitro and in vivo situations, expression of CCR6 or CCR7 was not associated with a particular subset. In conclusion, activated T-helper CD4+ T cells, by their release of cytokines, seem to have functional similarities with plasma cells secreting immunoglobulins.
During studies on the characterization of Th1-producing cytokines, we noticed the plasma cell appearance of some cytokine-producing T cells in RA synovium sections.5
To further clarify this subset, we decided to focus on its morphology and phenotype in both in vitro and in vivo situations. Activated Th CD4+ T cells were defined by the expression of two proinflammatory cytokines6
interleukin (IL)-17 and interferon (IFN)- using two in vitro models. The first model is the stimulation with phorbol myristate acetate (PMA) and phytohemagglutinin (PHA) for 4, 24, and 48 hours leading to a polyclonal activation of normal peripheral blood mononuclear cells (PBMCs). The second model is the oligoclonal activation with the superantigen Staphylococcus aureus enterotoxin B (SEB) of normal PBMCs during 4 hours leading to the isolation, by affinity matrix technology, of IFN--secreting CD4+ cell subsets.7-9
The characterization of IL-17- and IFN--producing cells was performed by immunocytochemistry, confocal microscopy, and transmission electron microscopy and extended to various normal and abnormal in vivo situations. We first looked at normal activated lymph nodes and then at inflammatory diseases such as RA and dermatomyositis (DM). DM is an idiopathic inflammatory myopathy considered as a CD4-driven disease with the involvement of Th1 proinflammatory cytokines.10,11
IL-17- and IFN--producing cells were defined by immunohistochemistry using the CD3 and CD4 T-cell markers. To study the migration patterns of these cells, we looked at the expression of two chemokine receptors, CCR6 and CCR7, involved with their associated ligands CCL20 and CCL19/CCL21 in the migration of T lymphocytes.12-15
In RA synovium, we have already shown the involvement of CCL20/CCR6 and CCL19-CCL21/CCR7 in the migration of immature and mature DC subsets, respectively.16
The results indicate that IL-17- and IFN--producing cells acquire a plasma cell-like morphology associated with a reduced expression of CD3 and the persistence of CD4 after in vitro polyclonal and oligoclonal activation. A similar morphology was observed in RA, DM, and activated lymph node sections. In these situations, Th1-cytokine production was associated with a similar phenotype as in plasma cells producing immunoglobulins.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
PBMCs were isolated by Ficoll-Hypaque gradient centrifugation and resuspended in RPMI 1640 culture medium (Invitrogen, Cergy-Pntoise, France) supplemented with 10% fetal calf serum (Invitrogen), penicillin/streptomycin (5 µl/ml), and fungizone (2 µl/ml). Cells were cultured at a concentration of 1 x 106/ml in complete culture medium in six-well microtiter plates (Nunc, Roskilde, Denmark) and were stimulated or not for 4, 24, and 48 hours with 5 ng/ml of PMA and 1 µg/ml of PHA. Cytospin-centrifuged unstimulated and stimulated PBMCs were fixed in 2% formaldehyde solution (Merck, Darmstadt, Germany).
Synovial samples were obtained from patients with RA, defined according to the revised criteria of the American College of Rheumatology (formerly, the American Rheumatism Association).17 To assess inflammatory synovium, samples were obtained from patients undergoing knee or wrist synovectomy, and not at a late stage such as for joint replacement. Muscle samples were obtained from patients selected on the basis of the presence of an inflammatory lesions typical of DM.18,19 Activated lymph nodes were negative for lymphoma.
For detection of cytokine-producing cells, samples were fixed in 4% phosphate-buffered paraformaldehyde and then embedded in paraffin. Four-µm sections were cut and mounted on glass slides. To detect antigen expression in paraffin-embedded sections, antigen retrieval procedures were performed, including incubation in either citrate buffer (10 mmol/L, pH = 6) or ethylenediaminetetraacetic acid buffer (1 mmol/L, pH = 8) followed by a microwave oven incubation for 3 minutes for three times.
Stimulation of Normal PBMCs with SEB—Isolation of IFN--Secreting Cells
Human PBMCs were isolated from fresh leukocyte filters obtained from the local blood bank by Ficoll-Paque plus (Amersham Biosciences, Sweden) density gradient centrifugation. Cells were stimulated in six-well plates at a density of 107 cells/ml with 1 µg/ml of SEB (Sigma-Aldrich, Vienna, Austria) in RPMI medium containing 10% human AB serum (PAA Laboratories, Vienna, Austria) at 37°C. For isolation of IFN--secreting cells, the affinity matrix technology (Miltenyi Biotec, Cologne, Germany) was applied according to the manufacturer’s protocol. In brief, after 4 hours of culture, cells were washed, labeled with IFN- catch antibody, diluted with prewarmed medium to 106 cells/ml, incubated for another 45 minutes at 37°C for cytokine secretion, washed, and labeled with IFN- detection (PE-coupled) antibody and surface markers CD4/CD8 (Becton Dickinson, Basel, Germany). For magnetic enrichment, cells were incubated with anti-PE-microbeads; magnetically labeled cells were separated from unlabeled using LS+MACS-columns (Miltenyi Biotec). For further purification, individual cell populations were sorted by a Becton Dickinson fluorescence-activated cell sorter (FACS-DIVA). Purity was checked on a FACScalibur (Becton Dickinson). Isolated cell populations wereIFN-+CD4+, IFN--CD4+, IFN-+CD4-, and IFN--CD4- SEB-stimulated cells and IFN--CD4+, and IFN--CD4- unstimulated cells. Finally, cells were washed once with cold phosphate-buffered saline (PBS) and fixed in the presence of 2% formaldehyde solution.
Detection of Cytokine-Producing Cells by Immunohistology
Paraffin-embedded sections of RA synovium, DM, and normal activated lymph nodes were treated in xylene and rehydrated in a gradient of ethanol (once in 99% ethanol, once in 95% ethanol, and once in H2O). Endogenous peroxidase activity was blocked with 3% hydrogen peroxide. The sections were then incubated with 5 µg/ml of a goat polyclonal anti-IL-17 (R&D Systems Europe, London, UK), or of a rabbit polyclonal anti-IFN- antibody (Genzyme, Cambridge, MA). In negative control sections, the primary antibodies were omitted or irrelevant antibody (goat or rabbit serum) was applied at the same concentration as the primary antibody. After overnight incubation at 4°C and washing, the sections were incubated with biotinylated mouse anti-goat IgG or mouse anti-rabbit IgG antibodies for 30 minutes, followed by streptavidin-peroxidase complex (DAKO, Glostrup, Denmark) for 15 minutes and 3,3' diaminobenzidine tetrahydrochloride (DAB) (DAKO) for 20 minutes. The sections were then counterstained with Mayer’s hematoxylin.
For double staining with anti-IL-17 and anti-IFN- antibodies, paraffin-embedded sections were simultaneously incubated with biotinylated goat polyclonal anti-IL-17 (R&D) and rabbit polyclonal anti-IFN- (Genzyme) antibodies. In negative control sections, one of the two primary antibodies was omitted. After overnight incubation at 4°C and washing, the sections were incubated with streptavidin-fluorescein isothiocyanate (DAKO) and CyaninIII goat anti-rabbit Ig (DAKO) throughout 45 minutes. The samples were then examined by fluorescence microscopy.
Characterization of Cytokine-Producing Cells in RA Synovium and in PBMCs
To clarify the morphology and phenotype of IL-17- and IFN--producing cells, double-labeling experiments were performed by first staining for cytokines, followed by immunophenotyping for T-cell markers with mouse monoclonal anti-CD3 (DAKO), and anti-CD4 (Novocastra, Newcastle, England), for B-cell markers with anti-CD20 (DAKO), anti-CD38 (DAKO), anti- (Eurodiagnostica, Arnhem, The Netherlands), and anti- (Eurodiagnostica), and for chemokine receptors with anti-CCR6 (R&D Systems), and anti-CCR7 (Becton-Dickinson) antibodies. After staining for IL-17 or IFN- as described above, incubation with one of these monoclonal antibodies was performed, then purified rabbit anti-mouse IgG (DAKO) and mouse alkaline phosphatase anti-alkaline phosphatase (DAKO) were applied. Alkaline phosphatase was revealed using Fast Blue as chromogen (blue color; Vector Laboratories, Peterborough, UK). Quantification of positive cells on cytospin slides was performed using a Lucia image analyzer (Nikon, France).
To further clarify the phenotype of cytokine-producing cells, immunofluorescence techniques were performed using PE-anti-IL-17, or PE-anti-IFN- (R&D Systems) and fluorescein isothiocyanate-anti-CD3, -anti-CD4, -anti-CCR6, or -anti-CCR7 antibodies (DAKO). Fluorescent images were observed under a laser-scanning confocal microscope (Leica TCS SP2).
For electron microscopic examination, the sorted cells were quickly washed in PBS, and immediately fixed with 4% paraformaldehyde and 2% glutaraldehyde. The cells were postfixed with 1% OsO4 for 2 hours, alcohol-dehydrated, and embedded in EPON. Thin sections were collected on nickel grids and stained with uranyl acetate and lead citrate. The prepared samples were observed under a transmission microscope.
Measurement of IL-17 and IFN- Levels on PBMC Supernatants
IL-17 and IFN- were measured by two-site sandwich enzyme-linked immunosorbent assay. Supernatants or serial dilutions of IFN- standard (Schering-Plough Research Institute) were incubated for 60 minutes at 20°C in 96-well microtiter plates (Nunc), which were coated overnight at 4°C with the mouse A35 anti-IFN- monoclonal antibody, and saturated for 60 minutes with PBS-0.05% Tween 20 to 5% bovine serum albumin. After washing, a biotinylated mouse B27 anti-IFN- monoclonal antibody (60 ng/ml) was added and cultures were incubated for 90 minutes at 20°C. After subsequent incubation with peroxidase-coupled streptavidin and visualization with orthophenylenediamine (Sigma), the plates were read at 492 nm. Levels of IL-17 in PBMC supernatants were measured by enzyme-linked immunosorbent assay (Medgenix IL-17 cytoscreen assay; BioSource Europe S.A., Nivelles, Belgium). The plates were read at 450 nm. Sensitivity of the assay was 2 pg/ml.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
We first used a polyclonal activation with PMA and PHA. Normal PBMCs were stimulated with PMA (5 ng/ml)/PHA (1 µg/ml) for 4, 24, and 48 hours. Immunostaining using anti-IL-17 and anti-IFN- antibodies was performed on cytospin slides. Both IL-17- and IFN--producing cells after 4 hours of stimulation had a T-cell phenotype with a central large nucleus and a reduced cytoplasm (Figure 1, A and B
, respectively). After 24 hours of stimulation, some IL-17- and IFN--producing cells had a plasmacytoid-like appearance with a remote nucleus in a large cytoplasm (Figure 1, C and D
, respectively). After 48 hours, all Th1 cytokine-producing cells had acquired this plasma cell-like morphology (Figure 1, E and F)
.
|
was detected. When PBMCs were stimulated, both cytokines were detected in culture supernatants after 4, 24, and 48 hours. The profile of secretion was quite similar for IL-17 and IFN- (Table 1)
, with a time-dependent enhanced concentration. However, the concentrations of IFN- were approximately threefold higher than those of IL-17 (IFN-, mean ± SEM, 24.3 ± 5.9 ng/ml versus IL-17, 7.4.± 1.9 ng/ml), sevenfold (IFN-, 70 ± 8.2 ng/ml versus IL-17, 9.8.± 0.7 ng/ml), and 10-fold (IFN-, 168 ± 11.4 ng/ml versus IL-17, 17.8 ± 0.3 ng/ml) after 4, 24, and 48 hours, respectively. When combined with the cell appearance described above, the time-dependent enhanced concentrations of IL-17 and IFN- in PBMC supernatants was linked to the acquisition of the plasma cell-like morphology.
|
in PBMC culture supernatants, the production of IL-17 and IFN- at a single-cell level was estimated by quantifying the number of IL-17+ and IFN-+ cells on cytospin slides using a Lucia image analyzer (Table 1)
. In the same way, a time-dependent enhanced production was observed at a single-cell level. In parallel with the acquisition of the plasma cell-like morphology, the single-cell production of IFN- (from 1.4 to 3 pg) and IL-17 (from 1.6 to 2.5 pg) was up-regulated (Table 1)
. Thus, the difference in levels in supernatants between the two cytokines was related to a difference in cell frequency, the production per cell remaining identical for each cytokine.
Next, PBMCs were exposed to an oligoclonal activation with the superantigen SEB. Normal PBMCs stimulated or not with the superantigen SEB were selected according to the expression of IFN- and CD4 using the affinity matrix technology and purified by fluorescence-activated cell sorting into the four subsets expressing or not IFN- and CD4. After such purification, staining with anti-IL-17 antibody was performed on six different cell populations: IFN-+CD4+, IFN--CD4+, IFN-+CD4-, and IFN--CD4- SEB-stimulated cells and IFN--CD4+, IFN--CD4- unstimulated cells.
As observed with polyclonal activation after 4 hours of stimulation, the predominant morphology of the IL-17+ and IFN-+ cells was that of a classical T-cell phenotype with a large nucleus in a reduced cytoplasm (Figure 1, G and H
, respectively). IL-17 was detected in both IFN-+CD4+ and IFN--CD4+ SEB-stimulated cells but not in IFN-+CD4-, and IFN--CD4- SEB-stimulated cells and IFN--CD4+, IFN--CD4- unstimulated cells (data not shown). Transmission electron microscopy analysis of sorted cells showed that IFN--CD4+ cells (stimulated or not) had the same classical T-cell morphology (Figure 1I)
. After 4 hours of stimulation, most of the IFN-+CD4+ cells showed this T-cell morphology. However, some IFN-+CD4+ cells stimulated with SEB for 4 hours showed a plasmacytoid-like appearance with a remote nucleus in a large cytoplasm (Figure 1, J and K)
.
The Th1-Producing T Cells Lose the Expression of CD3 but Not that of CD4 after Oligoclonal and Polyclonal Activation
To clarify the phenotype of IL-17- or IFN--producing cells, double staining with anti-IL-17 or anti-IFN- and anti-CD4 or anti-CD3 antibodies were performed on activated PBMCs after 4, 24, and 48 hours of stimulation with PMA/PHA. CD3 was still expressed on IL-17+ and IFN-+ cells after 4 hours of stimulation (Figure 2, A and B)
. This expression decreased after 24 hours (Figure 2C)
and was not detected anymore after 48 hours of stimulation on both IL-17- and IFN--producing cells (Figure 2, D and E)
, whereas that of CD4 did not change (Figure 2
; F to I, respectively).
|
-CD4+ and IFN-+CD4+ cell subsets, after 4 hours of stimulation with the superantigen SEB, started to decrease on IFN-+CD4+ cell subset (Figure 2J)
as indicated by the lower staining intensity when compared to that of CD3 staining on IFN--CD4+ cell subset (Figure 2K)
.
This study was further extended by a fluorescence-activated cell sorting analysis looking at the kinetics of CD3 expression from 0 to 6 hours after SEB stimulation of CD4+ T cells. The dot-plot image in Figure 3
shows CD3 expression versus IFN- staining gated on CD4+ cells isolated from PBMCs stimulated from 0 to 6 hours. Progressive loss of CD3 expression was observed in both IFN-+ and IFN-- subsets but was particularly clear for the IFN-+ subset. At 6 hours, 37% of IFN-+CD4+ cells (2.93 of 6.98) were CD3-negative versus 8% for the IFN-- cells (Figure 3)
.
|
This in vitro activation may represent an artificial situation, in particular not representing the cell-cell interactions observed in vivo, in lymphoid organs and local inflammatory lesions. Accordingly, we compared the phenotype observed after in vitro activation to that found in sections of activated reactive lymph nodes, RA synovium, and DM.
In activated lymph nodes, IL-17 or IFN-+ cells were detected in the T-cell zone out of germinal centers (Figure 4A)
. Both subsets had the plasmacytoid-like morphology described in vitro (Figure 4A
, inset). In RA synovium, when studied at high magnification, the IL-17- and IFN--producing cells had exactly the same plasma cell-like morphology as observed for PBMCs activated with PMA/PHA for 24 and 48 hours (insets of Figure 4, B and C
, respectively). These cells were either isolated (Figure 4B)
or accumulated as part of a lymphocytic infiltrate (Figure 4C)
.
|
-producing cells were detected in lymphocytic infiltrates in the endomysium (Figure 4D)
but at a lower frequency compared to RA synovium. These cells also had a plasma cell-like morphology (Figure 4D
, inset).
To further characterize the Th1 cytokine-producing T cells in RA synovium, double staining was performed with anti-IL-17 or anti-IFN- and anti-CD3 or anti-CD4 antibodies. Here again, IL-17- and IFN--producing cells expressed CD4 (Figure 4E)
but not CD3 (Figure 4F)
, as observed with PBMCs activated for 24 hours.
As plasma cells are commonly found in these in vivo situations, double staining for cytokines and B-cell lineage markers was performed using CD20 as a B-cell marker and CD38, / light chains as plasma cell markers. Double staining with anti-IL-17 or anti-IFN- and anti-CD20, CD38, / light chains showed that none of the IL-17+ or IFN-+ cells expressed B/plasma cell markers (Figure 4
; G to J, respectively). These results excluded B cells and plasma cells as IL-17- or IFN--producing cells.
Co-Expression of IL-17 and IFN- in RA Synovium
Double staining of RA synovium sections with anti-IL-17 and anti-IFN- antibodies indicated that some cells could be expressing at the same time both IL-17 and IFN- (as indicated by the arrows in Figure 4, K and L
, respectively), or IFN- but not IL-17 (Figure 4L
, arrowheads). On the contrary, cells secreting IL-17 alone and not IFN- were not observed (Figure 4, K and L)
. However, simultaneous secretion appeared to be a rare event when compared to a single secretion of IFN-. Such profile of secretion was also observed in IFN--producing cells isolated after stimulation with SEB. Staining with anti-IL-17 on these IFN-+-isolated T cells showed that some IFN-+CD4+ T cells can also produce IL-17 (Figure 1G)
.
Some of the IL-17- and IFN--Producing Cells Express the Chemokine Receptors CCR6 and CCR7 after Oligoclonal and Polyclonal Activation and in RA Synovium
Migration of T cells toward inflammatory sites is under the control of chemokines acting on membrane receptors. Accordingly, we focused on the expression on IL-17- and IFN--producing cells of two chemokine receptors, CCR6 and CCR7, known to be involved with their associated ligands CCL20 and CCL19/CCL21 in the migration of T cells. After stimulation with PMA/PHA for 4, 24, and 48 hours and whatever the duration of stimulation, some IL-17 and IFN--producing cells could express the CCR6 receptor [Figure 5, A
(arrow) and G]. However, this was not a subset marker because some IL-17- and IFN--producing cells did not express CCR6, and some CCR6+ cells did not produce IL-17 or IFN- (Figure 5, A and G)
. As for CCR6, double staining with anti-IL-17 or anti-IFN- and anti-CCR7 antibodies revealed the presence of CCR7+Th1-producing cells [Figure 5, B
(arrow) and H], CCR7-Th1-producing cells and CCR7+ cells nonproducing IL-17 or IFN- (Figure 5, B and H)
. Double staining using anti-IL-17 and anti-CCR6 or anti-CCR7 antibodies of IFN--producing CD4+ T cells stimulated with SEB showed that some IL-17+IFN-+CD4+ T cells expressed CCR6 and CCR7 [Figure 5, C and D
(arrows), respectively].
|
+ cells (Figure 5E
, arrow) such as IL-17- and IFN-- cells (Figure 5E)
. Similarly, CCR7 was observed in Th1 cytokine-producing cells (Figure 5F
, arrow) such as IL-17- and IFN-- cells (Figure 5F)
, indicating that the chemokine receptors do not delineate Th1-secreting cell subsets. |
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
First, we focused on the phenotype and morphology of IL-17- and IFN--producing cells in normal PBMCs after polyclonal and oligoclonal activation. This study was extended to normal activated lymph nodes and to inflammatory diseases such as RA and DM. We looked at the expression by immunohistochemistry of the CD3 and CD4 T-cell markers, the CD20, CD38, and B-cell lineage markers, and the chemokine receptors CCR6 and CCR7.
A classical T-cell morphology was observed in IL-17- and IFN--producing cells when stimulated for a short-time period (4 hours) with PMA/PHA or with the superantigen SEB. Later, when studied at high magnification, IL-17- and IFN--producing cells showed a plasma cell-like morphology, with a remote nucleus in a large cytoplasm, in activated PBMCs stimulated with PMA/PHA for 24 and 48 hours and also in normal activated lymph nodes, RA, and DM. These IL-17- or IFN--producing cells looked like but were not plasma cells, as indicated by the lack of expression of the CD20 B-cell marker, and the CD38, and light chain plasma cell markers. For B cells, the acquisition of the plasma cell morphology has been associated with the start of immunoglobulin production. In the same way, the time-dependent enhanced concentrations of IL-17 and IFN- in PBMC supernatants measured by enzyme-linked immunosorbent assay was linked to the acquisition of the plasma cell morphology. As for B cells, the plasmacytoid appearance of Th cells was associated with a secretory activity of cytokines in this case. When expressed at a single cell level, production of IFN- or IL-17 was identical, and differences in supernatant levels were explained by a higher frequency of IFN-- or IL-17-producing cells.
Regarding the expression of the CD3 T-cell marker, IL-17- and IFN--producing cells still express CD3 until 4 hours of polyclonal or oligoclonal activation. But after 24 and 48 hours of stimulation with PMA/PHA, IL-17- or IFN--producing cells lose the CD3 as also observed in normal activated lymph nodes, RA synovium, and DM. There was a link between the reduced expression of CD3 and the plasma cell morphology of Th1+ cells. At 4 hours of stimulation, the classical T-cell morphology was associated with the expression of CD3, which disappeared with the appearance of the plasmacytoid-like morphology after 24 hours. As for the acquisition of the plasma cell morphology, a parallel can be drawn between B- and T-cell lineages regarding the expression of molecules on their membrane. When B cells become plasma cells, they lose their membrane immunoglobulin and start to secrete. Here for Th1 cells, the plasmacytoid-like appearance was associated with the loss of CD3 expression. As opposed to B cells, the TCR is not secreted as a soluble form after TCR activation. The TCR loss would imply a loss of interactions with antigen-presenting cells, after TCR activation. This lack of interaction could result in the persistence of the release of Th1 cytokines perpetuating then the inflammatory and destructive processes in RA or DM.
When we compared the in vitro models with the in vivo situations, we observed the same pattern in RA and on PBMCs stimulated with PMA/PHA for 24 and 48 hours. The level of activation in RA appears to be equivalent to a strong stimulation with PMA (5 ng/ml)/PHA (1 µg/ml) during 24 hours. In normal activated lymph nodes and inflammatory diseases such as RA and DM, the cytokine microenvironment and cell interactions leading to Th cell activation are potent contributors to chronicity.
Migration of T cells is critical in the pathogenesis of RA and DM. Thus we looked at the expression of two chemokine receptors CCR6 and CCR7 on IL-17- or IFN--producing cells in both in vitro and in vivo conditions. In both situations, only some IL-17+ cells express the CCR6 or CCR7 receptors indicating that these receptors are not subset markers of T helper cells. This reflects also the heterogeneity of chemokine receptor expression on effector T cells, as observed in another in vitro study looking at such expression on PBMCs stimulated with PMA and ionomycin for 4 hours.21
It has been shown also that the in vitro migration of human and murine CD4+- IFN--, IL-4-, and IL-10-producing cells were comparable to that of naïve CD4+ cells in response to CCL19 and CCL21.22
This indicates that CCR7 is also expressed on activated CD4+ T cells.22
In RA synovium, the close association between CCL21 and CCL20 with IL-17+CCR7+ and IL-17+CCR6+ cells, respectively, suggests the contribution of CCL21 and CCL20 to the migration of CCR7+ and CCR6+ Th1-producing cells into RA synovium.
In conclusion, Th1-producing cells are rather rarely found in normal activated and inflammatory conditions. As for plasma cells compared to B cells, their differentiation into producing cells implies an important secretory activity at a single level.23,24
Despite such low distribution, IL-17- and IFN--producing cells, with this plasma cell-like morphology can still represent major actors of the inflammatory and destructive processes in inflammatory diseases. This makes proinflammatory cytokine-producing T cells a potential therapeutic target.
|
Footnotes |
|---|
Supported by a grant from la Fondation pour la Recherche Médicale (to G. P.).
Accepted for publication October 7, 2003.
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
 |
|
 |
|
  S. P. Singh, H. H. Zhang, J. F. Foley, M. N. Hedrick, and J. M. Farber Human T Cells That Are Able to Produce IL-17 Express the Chemokine Receptor CCR6 J. Immunol., January 1, 2008; 180(1): 214 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Zrioual, M.-L. Toh, A. Tournadre, Y. Zhou, M.-A. Cazalis, A. Pachot, V. Miossec, and P. Miossec IL-17RA and IL-17RC Receptors Are Essential for IL-17A-Induced ELR+ CXC Chemokine Expression in Synoviocytes and Are Overexpressed in Rheumatoid Blood J. Immunol., January 1, 2008; 180(1): 655 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Iwamoto, S.-i. Iwai, K. Tsujiyama, C. Kurahashi, K. Takeshita, M. Naoe, A. Masunaga, Y. Ogawa, K. Oguchi, and A. Miyazaki TNF-{alpha} Drives Human CD14+ Monocytes to Differentiate into CD70+ Dendritic Cells Evoking Th1 and Th17 Responses J. Immunol., August 1, 2007; 179(3): 1449 - 1457. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
